### **NeuroNEXT Network**

### **Standard Operating Procedure (SOP)**

# Quality Assurance Audits Version 4.0 SOP NN QA 801

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

Signature and Date:

Christopher S. Coffey Coffey
Reason: I approve this document
Date: Mar 8, 2024 07:59 CST

08-Mar-2024

Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)

Signature and Date:

Merit Cudkowicz

Electronically signed by: Merit Cudkowicz Reason: I approve this document Date: Feb 22, 2024 18:04 CST

22-Feb-2024

Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)

Signature and Date:

Marianne Chase

Electronically signed by: Marianne Chase Reason: I approve this document Date: Feb 22. 2024 14:54 EST

22-Feb-2024

Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

NN QA 801 Page 1 of 7

SOP 801: NN QA 801

Version No. 4.0

Issue Date: 01Mar2024 Effective Date: 15Apr2024 QUALITY ASSURANCE AUDITS Supersedes Document Version: 3.0

Effective Date: 08Apr2023

**Signature and Date:** 

Dixie Ecklund

Electronically signed by: Dixie Ecklund Reason: I approve this document Date: Feb 24, 2024 17:12 CST

24-Feb-2024

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

بهمعساريسي

Electronically signed by: Stacey Grabert Reason: I approve this document Date: Feb 22, 2024 15:13 EST

22-Feb-2024

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

Joan Ohayon

Electronically signed by: Joan Ohayon Reason: I approve this document Date: Mar 11, 2024 11:14 EDT

11-Mar-2024

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program

Official)

NN QA 801 Page 2 of 7

SOP 801: NN QA 801
Version No. 4.0
Issue Date: 01Mar2024
Effective Date: 15Apr2024

Supersedes Document Version: 3.0
Effective Date: 08Apr2023

Effective Date: 08Apr2023

#### 1. POLICY

The Data Coordinating Center (DCC) and/or the Clinical Coordinating Center (CCC) may arrange for periodic audits of ongoing and completed research for the NeuroNEXT Network at Clinical Study Sites (CSS), as required per protocol. The CCC and, when applicable, the DCC will act on findings of concern with immediate corrective actions, as well as long-range process improvements.

Audits of CSS will not be performed by personnel responsible for conducting site monitoring visits. Auditors may use procedures outlined in NeuroNEXT SOPs or other mutually agreed-upon procedures, working papers, or tools provided by the auditor to conduct and document the audit.

#### 2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

#### 3. ROLES AND RESPONSIBILITIES

As required by a NeuroNEXT protocol, the Sponsor, the DCC, and/or the CCC may conduct auditrelated activities such as:

- Determining if audits of the CSS are needed, according to the protocol and in conjunction with the PPI and/or Sponsor
- Identifying a trained and qualified auditor to conduct the program audit; this individual may be either a DCC or CCC employee, or an outside contractor
- Ensuring that the auditor is informed of the requirements for the audit, and responsibilities in performing the audit
- Providing access to all relevant documentation necessary for carrying out a thorough audit, as determined by the PPI and/or Sponsor, DCC and CCC Leadership, as well as the CCC Quality Assurance (QA) team
- Ensuring that audits are scheduled and completed if appropriate funding is available
- Fully cooperating with QA audits by any authorized third party
- Developing and implementing Corrective Action and Preventative Action (CAPA) plans for any issues identified by an auditor.

As required by a NeuroNEXT protocol, a CSS auditor may be responsible for audit activities that include, but are not limited to, the following:

- Preparing for a CSS audit (as applicable)
- Conducting the audit according to applicable NeuroNEXT SOPs and regulatory requirements
- Reviewing preliminary audit observations with the PPI and the DCC and CCC Leadership

NN QA 801 Page 3 of 7

- Documenting observations in an audit report
- Submitting the final audit report to the PPI and/or Sponsor, the DCC PI, the CCC PI, and other applicable entities that may be designated by the DCC PI and the CCC PI.

As required by a NeuroNEXT protocol and if applicable to a study, the DCC and/or CCC is/are responsible for maintaining audit reports, and for maintaining a list of audit dates (to present to an FDA inspector).

Appropriate personnel from the CSS, DCC and CCC are responsible for developing and maintaining CAPA plans for any issues that are identified during a CSS audit.

The Study Team is responsible for following up on all corrective actions to ensure resolution.

The responsibility to conduct any or all of these activities may be delegated at the discretion of the PPI/Sponsor to the DCC and/or CCC, or to subcontractors of the DCC or CCC. Those individuals and entities also take on responsibility for meeting regulatory requirements on behalf of the PPI/Sponsor, but the PPI/Sponsor has the ultimate responsibility, and must therefore supervise those delegated activities effectively.

#### 4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 312.54	General Responsibilities of Sponsors
ICH E6, 2.13	The Principles of ICH GCP
ICH E6, 5.1	Quality Assurance and Quality Control
ICH E6, 5.19	Audit
ICH E6, 5.20	Noncompliance
FDA	Compliance Policy Guide 7151.02

#### 5. REFERENCES TO OTHER APPLICABLE SOPS

NN GA 105	Vendor Selection and Agreements
NN RA 202	Trial Master File Maintenance and Auditing
NN RA 203	Site Regulatory Binder Maintenance
NN SS 402	Site Initiation Visits and Site Training
NN SS 403	Routine Monitoring Visits
NN SS 404	Site Performance Monitoring
NN SS 406	Suspension or Early Termination of a Study or a Clinical Site
NN QA 802	Quality Management

#### 6. ATTACHMENTS AND REFERENCES

NN QA 801 - A Document History

NN QA 801 Page 4 of 7

SOP 801: NN QA 801 Version No. 4.0 Issue Date: 01Mar2024 Effective Date: 15Apr2024	QUALITY ASSURANCE AUDITS	Supersedes Document Version: 3.0 Effective Date: 08Apr2023
---	-----------------------------	---

#### 7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

**CAPA** Corrective Action and Preventative Action CCC Clinical Coordinating Center at Massachusetts General Hospital CSS Clinical Study Site that conducts research for a NeuroNEXT protocol DCC Data Coordinating Center at The University of Iowa **FDA** US Food and Drug Administration PPI Protocol Principal Investigator **TMF** Trial Master File QΑ **Quality Assurance** QM **Quality Management** 

#### 8. SPECIFIC PROCEDURES

#### A. Auditing a Clinical Study Site (CSS)

#	Who	Task	Attachment/ Reference	Related SOP
1.	Study Team	If it is determined that a CSS audit is necessary, confirm that funding is available prior to scheduling the audit.		
2.	Sponsor	Select an in-house auditor, an external auditor, or delegate responsibility to the CCC and/or DCC per contract to conduct the audit on behalf of the Sponsor.		
3.	CCC and DCC	Work with the auditor and the clinical site to schedule the audit.		
4.	Study Team	If an external auditor is used, and as applicable to the firm, review the firm's SOPs, audit report process, and/or a Scope of Work document to ensure that they are adequate. Alternatively, require the auditor to follow the NeuroNEXT SOP for conducting investigative site audits.		NN GA 105 NN SS 403
5.	DCC / CCC Personnel	Instruct the auditor to meet with the investigator (and staff) to review the purpose and scope of the audit and sign a site monitoring log to document the visit.		

NN QA 801 Page 5 of 7

SOP 801: NN QA 801
Version No. 4.0
Issue Date: 01Mar2024
Effective Date: 15Apr2024

Supersedes Document Version: 3.0
Effective Date: 08Apr2023

Supersedes Document Version: 3.0
Effective Date: 08Apr2023

#	Who	Task	Attachment/ Reference	Related SOP
6.	DCC / CCC Personnel	After the audit is complete, request that the auditor provide a report and a completed checklist to the CCC and DCC, and review any significant findings and applicable evidence with the PPI, DCC/CCC Leadership and/or other appropriate staff.		
7.	CCC	File the reviewed and approved checklist in the TMF, if applicable.		NN RA 202
8.	Study Team	After reviewing the audit results, determine and document follow-up actions (e.g. no action indicated, data disqualification, study site termination).		NN SS 404 NN SS 406

NN QA 801 Page 6 of 7

SOP 801: NN QA 801

Version No. 4.0

Issue Date: 01Mar2024 Effective Date: 15Apr2024 QUALITY ASSURANCE AUDITS Supersedes Document Version: 3.0

Effective Date: 08Apr2023

#### Attachment NN QA 801 - A. Document History

	NeuroNEXT Network Standard Operating Procedure (SOP) Quality Assurance Audits SOP NN QA 801					
Version	Description of Modification	Reason or Justification for Modification	Issue Date	Effective Date	Reviewer(s)	
1.0 New		N/A	06Apr2012	06May2012	N/A	
2.0	Removed procedures for internal audits and references to Project Work Instructions (PWIs). Revised and condensed Roles and Responsibilities section. Clarified that CSS audits may be conducted by the Sponsor, by an external auditor, or by the DCC and/or CCC at the request of the Sponsor per contract. Clarified that the CCC and DCC are responsible for developing and maintaining CAPA plans for any issues that are discovered during audits of CSS, and that the Study Team is responsible for following up on corrective actions to ensure resolution. Condensed and revised the procedures for CSS audits.	Updates for Version 2.0	21Sep2016	21Oct2016	N/A	
3.0	Updated "1996 ICH E6 Consolidated Guidance" to "2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2)". Updated signature block to accommodate for electronic signatures. Additional minor updates throughout.	Updates for version 3.0	22Feb2023	08Apr2023	Catherine Gladden	
4.0 Minor edits for clarity		Periodic Review	01Mar2024	15Apr2024	Preeti Paul	

NN QA 801 Page 7 of 7

### NN QA 801 Quality Assurance Audits v4.0 clean

Final Audit Report 2024-03-11

Created: 2024-02-22

By: Tania Leeder (tleeder@mgb.org)

Status: Signed

Transaction ID: CBJCHBCAABAAG0FdEw7w4ibGiWULuFP2qINbkUrCTKs4

Number of Documents: 1

Document page count: 7

Number of supporting files: 0

Supporting files page count: 0

### "NN QA 801 Quality Assurance Audits v4.0 clean" History

Document created by Tania Leeder (tleeder@mgb.org) 2024-02-22 - 7:50:49 PM GMT

Document emailed to christopher-coffey@uiowa.edu for signature 2024-02-22 - 7:52:58 PM GMT

Document emailed to cudkowicz.merit@mgh.harvard.edu for signature 2024-02-22 - 7:52:58 PM GMT

Document emailed to Marianne Chase (mchase@mgh.harvard.edu) for signature 2024-02-22 - 7:52:58 PM GMT

Document emailed to dixie-ecklund@uiowa.edu for signature 2024-02-22 - 7:52:58 PM GMT

Document emailed to Stacey Grabert (SGrabert@mgh.harvard.edu) for signature 2024-02-22 - 7:52:58 PM GMT

Document emailed to ohayonj@ninds.nih.gov for signature 2024-02-22 - 7:52:58 PM GMT

Marianne Chase (mchase@mgh.harvard.edu) authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2024-02-22 - 7:54:14 PM GMT

ocument e-signed by Marianne Chase (mchase@mgh.harvard.edu)

Signing reason: I approve this document

Signature Date: 2024-02-22 - 7:54:26 PM GMT - Time Source: server

🖰 Email viewed by christopher-coffey@uiowa.edu

2024-02-22 - 7:55:48 PM GMT

Stacey Grabert (SGrabert@mgh.harvard.edu) authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2024-02-22 - 8:13:20 PM GMT

Document e-signed by Stacey Grabert (SGrabert@mgh.harvard.edu)

Signing reason: I approve this document

Signature Date: 2024-02-22 - 8:13:31 PM GMT - Time Source: server

Email viewed by cudkowicz.merit@mgh.harvard.edu

2024-02-22 - 11:20:34 PM GMT

cudkowicz.merit@mgh.harvard.edu authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2024-02-23 - 0:04:17 AM GMT

Signer cudkowicz.merit@mgh.harvard.edu entered name at signing as Merit Cudkowicz

Document e-signed by Merit Cudkowicz (cudkowicz.merit@mgh.harvard.edu)

Signing reason: I approve this document

Signature Date: 2024-02-23 - 0:04:30 AM GMT - Time Source: server

Tania Leeder (tleeder@mgb.org) added alternate signer cscoffey@iowa.uiowa.edu. The original signer christopher-coffey@uiowa.edu can still sign.

2024-02-23 - 6:58:35 PM GMT

Document emailed to cscoffey@iowa.uiowa.edu for signature

2024-02-23 - 6:58:36 PM GMT

Tania Leeder (tleeder@mgb.org) added alternate signer ecklundd@uiowa.edu. The original signer dixie-ecklund@uiowa.edu can still sign.

2024-02-23 - 6:58:53 PM GMT

Document emailed to ecklundd@uiowa.edu for signature

2024-02-23 - 6:58:53 PM GMT

email viewed by cscoffey@iowa.uiowa.edu

2024-02-23 - 7:14:12 PM GMT

email viewed by ecklundd@uiowa.edu

2024-02-24 - 11:12:10 PM GMT

ecklundd@uiowa.edu authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2024-02-24 - 11:12:23 PM GMT

Signer ecklundd@uiowa.edu entered name at signing as Dixie Ecklund

2024-02-24 - 11:12:38 PM GMT

Document e-signed by Dixie Ecklund (ecklundd@uiowa.edu)

Signing reason: I approve this document

Signature Date: 2024-02-24 - 11:12:40 PM GMT - Time Source: server

Email viewed by cscoffey@iowa.uiowa.edu

2024-03-08 - 9:19:54 AM GMT- IP address: 172.226.137.0

cscoffey@iowa.uiowa.edu authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2024-03-08 - 1:58:42 PM GMT

Signer cscoffey@iowa.uiowa.edu entered name at signing as Christopher S. Coffey 2024-03-08 - 1:58:58 PM GMT- IP address: 128.255.113.139

Document e-signed by Christopher S. Coffey (cscoffey@iowa.uiowa.edu)

Signing reason: I approve this document

Signature Date: 2024-03-08 - 1:59:00 PM GMT - Time Source: server- IP address: 128.255.113.139

Email viewed by ohayonj@ninds.nih.gov

2024-03-11 - 3:14:06 PM GMT- IP address: 104.47.64.254

ohayonj@ninds.nih.gov authenticated with Adobe Acrobat Sign.

Challenge: The user opened the agreement.

2024-03-11 - 3:14:15 PM GMT

Signer ohayonj@ninds.nih.gov entered name at signing as Joan Ohayon

2024-03-11 - 3:14:27 PM GMT- IP address: 72.83.187.43

Document e-signed by Joan Ohayon (ohayonj@ninds.nih.gov)

Signing reason: I approve this document

Signature Date: 2024-03-11 - 3:14:29 PM GMT - Time Source: server- IP address: 72.83.187.43

Agreement completed.

2024-03-11 - 3:14:29 PM GMT